Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 10 - 26 tags : Trial save search
4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease to be Presented at NACFC 2022
Published: 2022-10-26 (Crawled : 21:00) - globenewswire.com
FDMT M | $25.29 2.06% 2.02% 630K
|
Health Technology
|
| O: 1.17%
H: 34.79%
C: 14.63%
fibrosis lung disease trial therapeutics molecular cystic fibrosis
DiaMedica Therapeutics Provides Update on ReMEDy2 Trial
Published: 2022-10-26 (Crawled : 21:00) - biospace.com/
DMAC | $2.46 -1.21% -1.22% 21K
|
Health Technology
|
| O: 0.7%
H: 2.8%
C: -0.69%
trial therapeutics update
Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022
Published: 2022-10-26 (Crawled : 13:20) - globenewswire.com
CYCC | $1.85 -5.38% 10K
|
Health Technology
|
| O: 3.01%
H: 6.57%
C: 5.84%
trial tumors phase 1
Anixa Biosciences Announces Commencement of Phase 1b Trial of its Breast Cancer Vaccine at Cleveland Clinic
Published: 2022-10-26 (Crawled : 13:00) - biospace.com/
ANIX | $3.12 0.65% 0.64% 33K
|
Health Technology
|
| O: 0.76%
H: 10.38%
C: 9.62%
vaccine breast trial cancer phase 2b
Surmodics Announces TRANSCEND Trial 24-Month Data to be Presented at VIVA 2022
Published: 2022-10-26 (Crawled : 13:00) - biospace.com/
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: 0.14%
H: 1.46%
C: 0.34%
SRDX | News | $26.47 0.3% 0.3% 55K
|
Health Technology
|
| O: 1.29%
H: 3.22%
C: 1.97%
trial transcend
New Analysis of UPLIZNA® (inebilizumab-cdon) Phase 3 Trial Data Demonstrates Importance of Reducing Plasmablasts to Help Prevent Neuromyelitis Optica Spectrum Disorder (NMOSD) Attacks
Published: 2022-10-26 (Crawled : 13:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.35%
H: 0.47%
C: -1.87%
uplizna trial
eFFECTOR Therapeutics Completes Enrollment in Second of Three Cohorts of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19
Published: 2022-10-26 (Crawled : 12:20) - globenewswire.com
EFTR | $1.645 -7.58% -8.21% 200K
|
|
| O: -0.33%
H: 6.4%
C: 4.7%
covid-19 treatment trial therapeutics phase 2b
Immutep Announces Independent Data Monitoring Committee Positive Recommendation to Continue TACTI-003 Trial as Planned
Published: 2022-10-26 (Crawled : 12:20) - globenewswire.com
IMMP | $2.25 2.27% 2.22% 90K
|
Health Technology
|
| O: 0.0%
H: 3.74%
C: 3.21%
tacti-003 trial positive
QSAM Biosciences Adds Rutgers Cancer Institute of New Jersey as Clinical Trial Site To Expand and Advance Study of CycloSam® in the Treatment of Bone Cancer
Published: 2022-10-26 (Crawled : 12:20) - globenewswire.com
QSAM | $7.78 -31.58% 12K
|
Manufacturing
|
| O: 0.0%
H: 0.0%
C: -7.72%
cyclosam treatment bone trial cancer study
Hepion Pharmaceuticals Announces Publication of Phase 2a ‘AMBITION’ Clinical Trial Results
Published: 2022-10-26 (Crawled : 12:20) - contravir.com
HEPA | News | $2.11 -0.09% -0.09% 73K
|
Health Technology
|
| O: -0.44%
H: 10.51%
C: 9.16%
pharmaceuticals trial results publication phase 2b
Kura Oncology Reports Preliminary Proof of Mechanism in Phase 1/2 Clinical Trial of Tipifarnib Plus Alpelisib in Head and Neck Squamous Cell Carcinoma
Published: 2022-10-26 (Crawled : 12:00) - globenewswire.com
KURA | $17.55 -0.74% -0.74% 1.3M
|
Health Technology
|
| O: 0.48%
H: 1.51%
C: -4.4%
trial plus cell carcinoma phase 1
Exelixis Announces Promising Initial Dose-Escalation Results from the First-in-Human Phase 1 JEWEL-101 Trial Evaluating XB002 in Patients with Advanced Solid Tumors at ENA 2022
Published: 2022-10-26 (Crawled : 11:00) - biospace.com/
EXEL | $22.51 0.09% 0.09% 2.3M
|
Health Technology
|
| O: -0.18%
H: 1.14%
C: -1.8%
jewel-101 xb002 trial tumors results phase 1
Olema Oncology Announces Complete ER Antagonist OP-1250 Continues to Demonstrate Robust Activity in Phase 1/2 Clinical Trial
Published: 2022-10-26 (Crawled : 08:00) - biospace.com/
OLMA | $9.91 0.1% 0.1% 740K
|
Health Technology
|
| O: 0.56%
H: 14.46%
C: 4.46%
op-1250 trial phase 1
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.